Hormone Receptor-Positive Breast Carcinoma

Hormone Receptor-Positive Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 36
Recruiting: 25
Ph III recruiting: 3
Growth YoY: —
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02003209	Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer	completed	Phase 3	315	National Cancer Institute (NCI)NIH	2	Aug 8, 2025	clinicaltrials

Data updated 23 days agoSource updated Aug 8, 2025source: clinicaltrials